Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):738-45. doi: 10.1177/1533317513520214. Epub 2014 Feb 13.

Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.

Author information

  • 1Cognoptix, Inc, Acton, MA, USA ckerbage@cognoptix.com.
  • 2Premiere Research Institute and Nova Southeastern University, West Palm Beach, FL, USA.
  • 3Banner Alzheimer's Institute, Phoenix, AZ, USA.
  • 4Miami Jewish Health Systems, Miami, FL, USA.
  • 5ATP Clinical Research Inc., Costa Mesa, CA, USA.
  • 6Cognoptix, Inc, Acton, MA, USA.

Abstract

We report the findings from a clinical trial in which a group of patients clinically diagnosed with probable Alzheimer's disease (AD) were discriminated from an age-matched group of healthy volunteers (HVs) with statistical significance (P<.001). The results from 20 patients with AD and 20 HVs were obtained by a Fluorescent Ligand Eye Scanning (FLES) technique that measures a fluorescent signature specific to an exogenous ligand bound to amyloid-β in the lens of the eye. Sensitivity and specificity of 85% and 95%, respectively, have been achieved in predicting clinical diagnosis. Additionally, amyloid brain imaging using florbetapir F18 positron emission tomography shows significant correlation with the results obtained in the eye. Results of the study demonstrate the safety of the FLES system.

KEYWORDS:

Alzheimer’s disease; amyloid PET imaging; amyloid-β; fluorescence spectroscopy; human lens

PMID:
24526759
DOI:
10.1177/1533317513520214
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center